AR101 Real-World Open-Label Extension Study

NCT ID: NCT03337542

Last Updated: 2021-11-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

243 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-18

Study Completion Date

2019-09-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 3, multi-center, North American, open-label, long-term, safety extension study for eligible subjects who received AR101 therapy in the ARC007 trial (NCT03126227) and completed the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peanut Allergy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

AR101 Characterized Peanut Allergen CPNA (Characterized Peanut Allergen) OIT (oral immunotherapy) Peanut Allergy Peanut-Allergic Children Desensitization Food Allergy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment arm description

Subjects will receive maintenance dosing with AR101. Maintenance doses are provided in sachets, where each sachet contains 300 mg of peanut protein. Subjects are to ingest 300 mg orally once a day during maintenance.

Group Type OTHER

AR101

Intervention Type BIOLOGICAL

AR101

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AR101

AR101

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Received AR101 in study ARC007
* Completed the ARC007 study
* Use of effective birth control by sexually active female subjects of childbearing potential

Exclusion Criteria

* Developed a clinically significant change in health status during the ARC007 study which in the opinion of the investigator would make the subject unsuitable for participation in this study.
* Receiving a prohibited medication or anticipated use of a prohibited medication \[e.g., angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers or calcium channel blockers\], any monoclonal antibody, any investigational peanut immunotherapy, or any other immunomodulatory therapy.
* Currently in the build-up phase of immunotherapy for any nonfood allergen.
* Currently participating in any other interventional clinical study outside of the ARC007 study that was just completed.
Minimum Eligible Age

4 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aimmune Therapeutics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Director of Regulatory Affairs

Role: STUDY_DIRECTOR

Aimmune Therapeutics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Center of Alabama

Birmingham, Alabama, United States

Site Status

Medical Research of Arizona

Scottsdale, Arizona, United States

Site Status

Banner University of Arizona Medical Center

Tucson, Arizona, United States

Site Status

Arkansas Children's Hospital

Little Rock, Arkansas, United States

Site Status

Jonathan Corren, M.D., Inc.

Los Angeles, California, United States

Site Status

Allergy & Asthma Associates of Southern California

Mission Viejo, California, United States

Site Status

Sean N. Parker Center for Allergy Research at Stanford University - Packard-El Camino Hospital

Mountain View, California, United States

Site Status

Peninsula Research Associates

Rolling Hills Estates, California, United States

Site Status

Allergy & Asthma Medical Group and Research Center

San Diego, California, United States

Site Status

Rady Children's Hospital, Div. Allergy & Immunology, UC San Diego

San Diego, California, United States

Site Status

UCSF, Benioff Children's Hospital - Allergy and Immunology

San Francisco, California, United States

Site Status

Allergy & Asthma Associates of Santa Clara Valley Research Center

San Jose, California, United States

Site Status

UCLA Medical Center, Santa Monica

Santa Monica, California, United States

Site Status

Bay Area Allergy

Walnut Creek, California, United States

Site Status

Children's Hospital Colorado

Aurora, Colorado, United States

Site Status

Asthma & Allergy Associates

Colorado Springs, Colorado, United States

Site Status

National Jewish Health

Denver, Colorado, United States

Site Status

Colorado Allergy & Asthma Centers, P.C.

Denver, Colorado, United States

Site Status

Children's National Medical Center

Washington D.C., District of Columbia, United States

Site Status

Sher Allergy Specialists - Center for Cough

Largo, Florida, United States

Site Status

Allergy Associates of the Palm Beaches

North Palm Beach, Florida, United States

Site Status

Sarasota Clinical Research Windom Allergy, Asthma and Sinus

Sarasota, Florida, United States

Site Status

University of South Florida Asthma, Allergy, and Immunology Clinical Research Unit

Tampa, Florida, United States

Site Status

Atlanta Allergy & Asthma Clinic

Marietta, Georgia, United States

Site Status

Idaho Allergy and Research

Eagle, Idaho, United States

Site Status

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Site Status

The University of Chicago Medicine, Comer Children's Hospital

Chicago, Illinois, United States

Site Status

Sneeze, Wheeze, & Itch Associates, LLC

Normal, Illinois, United States

Site Status

Deaconess Clinic Downtown

Evansville, Indiana, United States

Site Status

Family Allergy & Asthma Research Institute

Louisville, Kentucky, United States

Site Status

Chesapeake Clinical Research, Inc.

Baltimore, Maryland, United States

Site Status

Johns Hopkins Hospital, Pediatric Clinical Research Unit

Baltimore, Maryland, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Boston Children's Hospital

Boston, Massachusetts, United States

Site Status

University of Michigan Division of Allergy and Clinical Immunology

Ann Arbor, Michigan, United States

Site Status

Clinical Research Institute, Inc.

Plymouth, Minnesota, United States

Site Status

Children's Mercy on Broadway

Kansas City, Missouri, United States

Site Status

Atlantic Research Center

Ocean City, New Jersey, United States

Site Status

Princeton Center for Clinical Research

Skillman, New Jersey, United States

Site Status

Northwell Health System

Great Neck, New York, United States

Site Status

Univ. of Rochester Medical Center, Golisano Children's Hosp.

Rochester, New York, United States

Site Status

University of North Carolina at Chapel Hill, Clinical & Translational Research Center

Chapel Hill, North Carolina, United States

Site Status

Clinical Research of Charlotte

Charlotte, North Carolina, United States

Site Status

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Site Status

Bernstein Clinical Research Center

Cincinnati, Ohio, United States

Site Status

Oklahoma Institute of Allergy and Asthma Clinical Research, LLC

Oklahoma City, Oklahoma, United States

Site Status

Columbia Asthma & Allergy Clinic

Clackamas, Oregon, United States

Site Status

The Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status

National Allergy and Asthma Research, LLC

North Charleston, South Carolina, United States

Site Status

Specially for Children Allergy, Asthma and Immunology Clinic

Austin, Texas, United States

Site Status

Children's Health

Dallas, Texas, United States

Site Status

Western Sky Medical Research

El Paso, Texas, United States

Site Status

Texas Children's Hospital, Baylor College of Medicine

Houston, Texas, United States

Site Status

Virginia Mason Medical Center

Seattle, Washington, United States

Site Status

ASTHMA Inc. Clinical Research Center

Seattle, Washington, United States

Site Status

McMaster University Medical Center

Hamilton, Ontario, Canada

Site Status

Triple A Lab / Hamilton Allergy

Hamilton, Ontario, Canada

Site Status

Cheema Research Inc. (CRI)

Mississauga, Ontario, Canada

Site Status

Ottawa Allergy Research Corp

Ottawa, Ontario, Canada

Site Status

Gordon Sussman Clinical Research

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Nilsson C, Scurlock AM, Dellon ES, Brostoff JM, Pham T, Ryan R, Brown KR, Adelman DC, Aceves SS. Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy. J Allergy Clin Immunol Pract. 2021 Dec;9(12):4496-4501. doi: 10.1016/j.jaip.2021.07.048. Epub 2021 Aug 11. No abstract available.

Reference Type DERIVED
PMID: 34389504 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ARC011

Identifier Type: -

Identifier Source: org_study_id